Real-world outcomes and drug survival of brodalumab: results…
Emerging
0
Citations0
Refs2024
Year
Search Works
Work Details
- DOI 10.6084/m9.figshare.25648878
- OpenAlex ID W6958486020
- Type Article
- Language EN
- Published 01 Jan 2024
- Source Figshare
- Publisher Figshare (United Kingdom)
- Added 10 Oct 2025
- Updated 27 Oct 2026
External Links
MENU
0
Real-world outcomes and drug survival of brodalumab: results from the German Psoriasis Registry PsoBest
Article 2024 EN Green
Brodalumab, a human monoclonal antibody that targets interleukin-17 receptor A (IL-17RA), is approved in the US and EU for treatment of adults with moderate-to-severe plaque psoriasis. Although brodalumab has demonstrated efficacy and safety vs placebo in clinical trials of patients with psoriasis and psoriatic arthritis (PsA), real-world evidence is needed to evaluate long-term effectiveness and…
0
Citations
0
References
6
Authors
0.00
FWCI
Topics
Keywords
UN Sustainable Development Goals
1 SDGsAuthors & Affiliations
6 authors| # | Author | Institutions | ORCID |
|---|---|---|---|
| 1 | Lisa Schaeffer | — | — |
| 2 | Nesrine Ben‐Anaya | — | |
| 3 | Christina Sorbe | — | |
| 4 | Stephan Jeff Rustenbach | — | — |
| 5 | Mrowietz, Ulrich | — | — |
| 6 | Matthias Augustin | — | — |
Related Works
10Data: OpenAlex